/**/ RNS Number : 7858T IQ-AI Limited 25 June 2024 June 25, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Opens Expanded Access Program New cancer treatment with the potential to slow brain tumor growth is now available to patients in the US with relapsed/refractory histologic or molecular glioblastoma Imaging Biometrics, LLC
/**/ RNS Number : 3271Q IQ-AI Limited 29 May 2024 IQ-AI Limited (“IQ-AI” or the “Company”) Result of AGM IQ-AI Limited announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed. For information, the proxy votes received prior to the meeting were
/**/ RNS Number : 5528P IQ-AI Limited 23 May 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Major East Coast Health System Chooses IB Nimble for Their Brain Metastases Program of Excellence Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), today announces that a leading cancer centre located
/**/ RNS Number : 0655P IQ-AI Limited 20 May 2024 May 20, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Announces Second U.S. FDA Rare Pediatric Disease Designation Granted to GaM For the Treatment of Pediatric-Type Diffuse High Grade Glioma (“HGG”) Further to the announcements made on 8 November 2023 and
/**/ RNS Number : 8182O IQ-AI Limited 17 May 2024 May 17, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Software Enhances Clinical Decision-Making at Insel Gruppe AG Imaging Biometrics (IB), Elm Grove, WI, a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), announces the successful deployment of its state-of-the-art software
/**/ RNS Number : 9596N IQ-AI Limited 10 May 2024 May 10, 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Announces U.S. FDA Rare Pediatric Disease Designation Granted to GaM For the Treatment of atypical teratoid rhabdoid tumor (“ATRT”) Further to the announcement made on 8 November 2023, Imaging Biometrics (“IB”),
/**/ RNS Number : 0442N IQ-AI Limited 02 May 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Announces Expanded Access Program for Oral Gallium Maltolate Company initiating program based on phase 1 tolerability and safety results Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), has received
/**/ RNS Number : 4602M IQ-AI Limited 29 April 2024 IQ-AI Ltd (“IQ-AI” or the “Company”) Publication of Annual Report The Board of IQ-AI Ltd is pleased to announce the Company’s audited financial statements for the year ended 31 December 2023. The Annual Report will be available on the Company’s corporate website